Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years.
Assadi M, Rezaei S, Jafari E, Rekabpour SJ, Ravanbod MR, Zohrabi F, Amini A, Keshmiri S, Dadgar H, Ahmadzadehfar H. Assadi M, et al. Among authors: rekabpour sj. World J Nucl Med. 2020 Feb 27;19(1):15-20. doi: 10.4103/wjnm.WJNM_20_19. eCollection 2020 Jan-Mar. World J Nucl Med. 2020. PMID: 32190017 Free PMC article.
Peptide Receptor Radionuclide Therapy Using 177 Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment.
Kalantarhormozi M, Hassanzadeh S, Rekabpour SJ, Ravanbod MR, Jafari E, Amini A, Dadgar H, Mahmoudpour M, Nabipour I, Jokar N, Assadi M. Kalantarhormozi M, et al. Among authors: rekabpour sj. World J Nucl Med. 2022 Aug 16;21(3):215-221. doi: 10.1055/s-0042-1755412. eCollection 2022 Sep. World J Nucl Med. 2022. PMID: 36060085 Free PMC article.
Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action.
Assadi M, Rekabpour SJ, Amini A, Dadgar H, Nemati R, Gholamrezanezhad A, Nabipour I, Jafari E, Ahmadzadehfar H. Assadi M, et al. Among authors: rekabpour sj. Mol Imaging Radionucl Ther. 2021 Jun 3;30(2):107-109. doi: 10.4274/mirt.galenos.2020.69783. Mol Imaging Radionucl Ther. 2021. PMID: 34082512 Free PMC article.
Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers: A Preliminary Study.
Assadi M, Rekabpour SJ, Jafari E, Divband G, Nikkholgh B, Amini H, Kamali H, Ebrahimi S, Shakibazad N, Jokar N, Nabipour I, Ahmadzadehfar H. Assadi M, et al. Among authors: rekabpour sj. Clin Nucl Med. 2021 Nov 1;46(11):e523-e530. doi: 10.1097/RLU.0000000000003810. Clin Nucl Med. 2021. PMID: 34269729
11 results